dc.contributor.author | Butt, Julia | |
dc.contributor.author | Sánchez Pérez, María José | |
dc.date.accessioned | 2021-11-08T11:16:43Z | |
dc.date.available | 2021-11-08T11:16:43Z | |
dc.date.issued | 2021-04-20 | |
dc.identifier.citation | Julia Butt... [et al.] (2021) Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort, Gut Microbes, 13:1, DOI: [10.1080/19490976.2021.1903825] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/71363 | |
dc.description | The coordination of EPIC is financially supported by the
European Commission (DG-SANCO) and the International
Agency for Research on Cancer. The national cohorts are
supported by the Danish Cancer Society (Denmark); Ligue
Contre le Cancer, Institut Gustave Roussy, Mutuelle
Générale de l’Education Nationale, and Institut National de
la Santé et de la Recherche Médicale (INSERM) (France);
Deutsche Krebshilfe, Deutsches Krebsforschungszentrum,
and Federal Ministry of Education and Research (Germany);
the Hellenic Health Foundation (Greece); the Sicilian
Government, AIRE ONLUS Ragusa, AVIS Ragusa,
Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy,
and National Research Council (Italy); Dutch Ministry of
Public Health, Welfare and Sports (VWS), Netherlands
Cancer Registry (NKR), LK Research Funds, Dutch
Prevention Funds, Dutch ZON (Zorg Onderzoek
Nederland), World Cancer Research Fund (WCRF), and
Statistics Netherlands (the Netherlands); Nordic Centre of
Excellence programme on Food, Nutrition and Health.
(Norway); Health Research Fund (FIS), PI13/00061 to
Granada, PI13/01162 to EPIC-Murcia, Regional
Governments of Andalucía, Asturias, Basque Country,
Murcia, Navarra, and the Catalan Institute of Oncology
(Barcelona), Spain; Swedish Cancer Society, Swedish
Scientific Council, and County Councils of Skåne and
Västerbotten (Sweden); Cancer Research UK (C864/A14136
to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/
A290170 to EPIC-Oxford), Medical Research Council (MR/
N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/
M012190/1 to EPIC-Oxford (UK). The funding sources had
no influence on the design of the study; the collection, analysis, and interpretation of data; the writing of the report; or the
decision to submit the paper for publication.Support for this
study was also provided by the COST Action CA17118 supported
by COST (European Cooperation in Science and
Technology, www.cost.eu) to DJH. | es_ES |
dc.description.abstract | Experimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic
Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from
epidemiological studies is sparse. We therefore assessed the association of serological markers of
E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation
into Nutrition and Cancer (EPIC) study.
Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for
immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the
ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of
sero-positivity to E. coli and ETBF with CRC.
The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of
developing CRC (OR: 1.42; 95% CI: 1.05–1.91). Dual-positivity for both IgA and IgG to E. coli and
ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association
only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to
the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR:
1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with
CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal
carcinogenesis. These findings warrant further exploration in larger prospective studies and
within different population groups. | es_ES |
dc.description.sponsorship | European Commission (DG-SANCO) | es_ES |
dc.description.sponsorship | International
Agency for Research on Cancer | es_ES |
dc.description.sponsorship | Danish Cancer Society (Denmark) | es_ES |
dc.description.sponsorship | Ligue
Contre le Cancer, Institut Gustave Roussy, Mutuelle
Générale de l’Education Nationale, and Institut National de
la Santé et de la Recherche Médicale (INSERM) (France) | es_ES |
dc.description.sponsorship | Deutsche Krebshilfe, Deutsches Krebsforschungszentrum,
and Federal Ministry of Education and Research (Germany) | es_ES |
dc.description.sponsorship | Hellenic Health Foundation (Greece) | es_ES |
dc.description.sponsorship | Sicilian
Government, AIRE ONLUS Ragusa, AVIS Ragusa,
Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy,
and National Research Council (Italy) | es_ES |
dc.description.sponsorship | Dutch Ministry of
Public Health, Welfare and Sports (VWS), Netherlands
Cancer Registry (NKR), LK Research Funds, Dutch
Prevention Funds, Dutch ZON (Zorg Onderzoek
Nederland), World Cancer Research Fund (WCRF), and
Statistics Netherlands (the Netherlands) | es_ES |
dc.description.sponsorship | Nordic Centre of
Excellence programme on Food, Nutrition and Health.
(Norway) | es_ES |
dc.description.sponsorship | Health Research Fund (FIS), PI13/00061 to
Granada, PI13/01162 to EPIC-Murcia, Regional
Governments of Andalucía, Asturias, Basque Country,
Murcia, Navarra, and the Catalan Institute of Oncology
(Barcelona), Spain | es_ES |
dc.description.sponsorship | Swedish Cancer Society, Swedish
Scientific Council, and County Councils of Skåne and
Västerbotten (Sweden) | es_ES |
dc.description.sponsorship | Cancer Research UK (C864/A14136
to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/
A290170 to EPIC-Oxford), Medical Research Council (MR/
N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/
M012190/1 to EPIC-Oxford (UK) | es_ES |
dc.description.sponsorship | COST Action CA17118 supported
by COST (European Cooperation in Science and
Technology) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Taylor & Francis | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Colorectal cancer | es_ES |
dc.subject | Escherichia coli | es_ES |
dc.subject | Bacteroides fragilis | es_ES |
dc.subject | Serology | es_ES |
dc.subject | Prospective | es_ES |
dc.title | Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.1080/19490976.2021.1903825 | |
dc.type.hasVersion | VoR | es_ES |